[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656082":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":16,"studyPopulation":16,"armGroups":31,"interventions":42,"overallOfficials":16,"centralContacts":51,"locations":57,"responsibleParty":72,"collaborators":16,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":16,"eligibilityCriteria":81,"healthyVolunteers":78,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":16,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":16,"overallStatus":97,"whyStopped":16,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Medical University of Vienna","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Change in the Endometriosis-Health-Profile-30 (EHP-30) Score","The Score is used to measure the impact of Endometriosis on the quality of life. It is standardised on a scale from 0 to 100. 0 indicates the best health status whereas 100 indicates the worst health status.","from enrollment to the end of treatment at 150 days\"",[14],{"measure":15,"description":16,"timeFrame":17},"Change in Dysmenorrhea using the visual analogue scale (0-10)",null,"From enrollment to the end of treatment at 150 days",{"allocation":19,"interventionModel":20,"interventionModelDescription":21,"primaryPurpose":22,"observationalModel":16,"timePerspective":16,"maskingInfo":23},"RANDOMIZED","PARALLEL","Model Description","TREATMENT",{"masking":24,"maskingDescription":25,"whoMasked":26},"QUADRUPLE","Masking Description",[27,28,29,30],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[32,37],{"label":33,"type":34,"description":16,"interventionNames":35},"Control-Group","PLACEBO_COMPARATOR",[36],"Drug: Placebo",{"label":38,"type":39,"description":16,"interventionNames":40},"Drug-Group","ACTIVE_COMPARATOR",[41],"Drug: Desloratadine",[43,48],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":16},"DRUG","Desloratadine","5mg daily",[38],{"type":44,"name":49,"description":49,"armGroupLabels":50,"otherNames":16},"Placebo",[33],[52],{"name":53,"role":54,"phone":55,"phoneExt":16,"email":56},"Marina Stjepic","CONTACT","+431404065190","marina.stjepic@meduniwien.ac.at",[58],{"facility":5,"status":16,"city":59,"state":16,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Vienna","1090","Austria","AT",{"type":64,"coordinates":65},"Point",[66,67],16.37208,48.20849,{"lat":67,"lon":66},[70],{"name":53,"role":54,"phone":71,"phoneExt":16,"email":56},"+4314040065190",{"type":73,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"PRINCIPAL_INVESTIGATOR","René Wenzl","Ao. Univ.-Prof. Dr. med. univ. René Wenzl, MSc","100656082","phase-2-impact-of-the-antihistamine-desloratadine-on-the-quality-of-life-and-dysmenorrhea-in-patients-with-endometriosis-100656082",false,"NCT07821320","Impact of the Antihistamine Desloratadine on the Quality of Life and Dysmenorrhea in Patients With Endometriosis","Inclusion Criteria:\n\n* Female patients aged 18-50\n* By imaging (sonography or MRI) or surgery last 10 years confirmed endometriosis\n* EHP-30 Score \\> 40\n\nExclusion Criteria:\n\n* Subject is unable or unwilling to participate\n* History of malignant diseases\n* Current immunosuppressant treatment\n* History of allergies and\u002For usage of antihistaminic treatments\n* Postmenopausal women\n* Current hormonal treatment\n* Surgical treatment \\\u003C1year","FEMALE","18 Years","50 Years",{"count":86,"type":87},60,"ESTIMATED","INTERVENTIONAL",[90],"PHASE2","Endometriosis is a chronic inflammatory disease affecting approximately 10% of women in their reproductive years. It is characterized by the presence of endometrial-like tissue outside the uterine cavity. Current treatment options include hormonal therapies or surgical excision of the endometriotic lesions. Although these interventions often lead to a significant symptom relief, some patients still experience persistent pain or treatment-related adverse effects. Consequently, the management of dysmenorrhea and improvement of quality of life in patients with endometriosis remain a clinical challenge.\n\nDesloratadine is widely used for the treatment of allergic rhinitis or chronic urticaria. Recent studies suggest that desloratadine may also possess analgesic and anti-inflammatory properties. So far, however, no clinical studies have investigated its potential therapeutic effects in patients with endometriosis.\n\nTherefore, the present study aims to provide the first clinical assessment of the efficacy, safety and tolerability of desloratadine in patients with endometriosis.",[93,94,95,96],"Endometriosis","Endometriosis (Diagnosis)","Endometriosis and Dysmenorrhea","Endometriosis Associated Pelvic Pain","NOT_YET_RECRUITING","2026-09-15",{"date":100,"type":101},"2026-09-18","ACTUAL",{"date":103,"type":87},"2027-02",{"date":105,"type":87},"2028-05",{"name":5,"class":6},1]